Strategy for the Implementation of the Modern Digital Track-And-Trace System in Pharmaceutical Circulation

The circulation of pharmaceutical products represents one of the most sensitive and high-risk areas of the healthcare system. Fragmented and non-integrated control mechanisms across the stages from production to the final consumer significantly increase the risk of falsified and substandard pharmaceutical products entering the supply chain. Existing regulatory mechanisms are largely based on retrospective inspections, which limits the ability to ensure real-time transparency throughout the circulation process. Therefore, a scientifically grounded investigation of this issue is both relevant and necessary. This article analyzes the limitations of existing regulatory control mechanisms, evaluates the core features of international Track & Trace models, and identifies implementation approaches suitable for national conditions based on the findings. The objective of the study is to develop a scientifically substantiated national strategy for implementing a modern digital tracking system in the circulation of pharmaceutical products. In recent years, the implementation of modern digital Track & Trace systems has become a strategic priority in developed countries to address these challenges. Within the European Union, the Falsified Medicines Directive (FMD), and in the United States, the Drug Supply Chain Security Act (DSCSA), continuous tracking of pharmaceutical products based on unique identification has been established as a legal requirement. These systems enable the digital recording of the movement of each pharmaceutical package throughout the supply chain and facilitate timely and effective regulatory oversight. Direct replication of international practices at the national level often does not yield effective results. Legal frameworks, institutional structures, technological infrastructure, and the preparedness of market participants play a decisive role in the successful implementation of digital tracking systems. Consequently, the implementation of a Track & Trace system should be regarded not merely as a technological solution but as a comprehensive legal, institutional, and strategic approach.

MATERIALS AND METHODS

The material base of the study consists of national and international scientific publications related to digital tracking systems in pharmaceutical circulation, official documents of international organizations (WHO, European Commission, FDA), regulatory acts related to the EU Falsified Medicines Directive (FMD) and the U.S. Drug Supply Chain Security Act (DSCSA), as well as national legal acts regulating pharmaceutical circulation. In addition, analytical reports and open statistical data sources were utilized.

The study employed a systematic approach, enabling the pharmaceutical supply chain to be examined as an integrated system and allowing functional interconnections between its stages to be identified. A comparative analysis method was applied to assess existing regulatory mechanisms and digital tracking models, comparing the legal, institutional, and technological features of international Track & Trace systems with national practices. Furthermore, a regulatory and legal analysis was conducted to evaluate mandatory requirements, legal mechanisms, and institutional competencies governing the implementation of digital tracking systems. Content analysis was used to systematize the objectives, implementation mechanisms, and outcomes of digital tracking systems described in scientific literature and official documents. A structural-functional analysis identified the roles of key stakeholders involved in pharmaceutical circulation (manufacturers, importers, distributors, pharmacies, and regulatory authorities) and their functional interactions within the digital tracking system. Based on the obtained results, analytical generalizations were made and a phased strategic implementation model suitable for national application was conceptually formulated.

RESULTS AND DISCUSSION

For the first time at the national level, the necessity and strategic importance of implementing a modern digital Track & Trace system in pharmaceutical circulation have been scientifically substantiated. Continuous tracking of pharmaceutical products based on unique identification ensures transparency throughout the circulation process, facilitates the detection of falsified and substandard pharmaceutical products, and enhances the effectiveness of regulatory control. Analysis of international experience indicates that successful implementation of digital tracking systems extends beyond technological solutions and is directly linked to the clarity of the legal-institutional framework, data integration, and phased implementation mechanisms. The national implementation strategy proposed in this article strengthens existing control mechanisms and contributes to reducing risks in pharmaceutical circulation. The findings hold significant practical value in accelerating digital transformation within the pharmaceutical sector, improving drug safety, and optimizing regulatory processes. They may be widely applied in shaping future regulatory, legal, and institutional decisions. The findings of the study demonstrate that the implementation of a modern digital Track & Trace system is one of the most effective tools for enhancing regulatory control over pharmaceutical circulation. Analysis of international models confirms that continuous tracking of pharmaceutical products based on unique identification significantly reduces the risk of falsified and substandard pharmaceutical products entering the supply chain and improves the operational efficiency of state regulatory oversight. Comparative analysis shows that the effectiveness of digital tracking systems depends not only on technological solutions but also on the clarity of legal regulation, institutional coordination, and the readiness of market participants. In the national context, fragmented control mechanisms and limited data integration represent key implementation challenges The study revealed that the proposed phased implementation strategy preserves the core principles of international Track & Trace models while adapting them to national legal and institutional characteristics. The strategy emphasizes gradual implementation, the development of risk-based regulatory control mechanisms, and the strengthening of public–private sector cooperation. The proposed approach offers tangible opportunities to increase transparency in pharmaceutical circulation, optimize regulatory costs, and enhance drug safety. However, effective implementation requires continuous improvement of the regulatory framework and the phased development of technological infrastructure as essential prerequisites.

Table. Key Indicators for Assessing the Effectiveness of a Digital Track & Trace System